{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:54:32Z","timestamp":1790816072625,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,16]],"date-time":"2018-07-16T00:00:00Z","timestamp":1531699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Enterovirus 71 (EV71) is an aetiological agent responsible for seasonal epidemics of hand-foot-and-mouth disease, which causes considerable mortality among young children. Mucosal vaccines can efficiently induce secretory IgA at mucosal surfaces and thereby prevent or limit infection at the site of virus entry. CpG oligodeoxynucleotides (ODNs), which resemble bacterial DNA, can induce the innate immune response through activation of Toll-like receptor 9. Here, we used CpG ODNs as adjuvants to investigate an EV71 mucosal vaccine in mice. In the EV71\u2009+\u2009CpG group, the EV71-specific IgG and IgA titres in the serum, nasal wash, bronchoalveolar lavage fluid, and faeces were substantially higher than those in the EV71- and phosphate-buffered saline-treated groups. Moreover, the number of EV71-specific IgG- and IgA-producing cells was also higher in the EV71\u2009+\u2009CpG group. Furthermore, T-cell proliferative responses and interleukin-17 secretion were markedly increased when CpG-adjuvanted EV71 was delivered intranasally. More importantly, the induced antibodies neutralised infection by EV71 of the C2 genotype and crossneutralised infection by EV71 of the B4 and B5 genotypes. Lastly, human scavenger receptor class B, member 2-transgenic mice intranasally immunised with the CpG-adjuvanted EV71 vaccine resisted a subsequent lethal challenge with EV71, indicating that CpG was an effective intranasal adjuvant for EV71 mucosal-vaccine development.<\/jats:p>","DOI":"10.1038\/s41598-018-28281-5","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T07:25:04Z","timestamp":1531207504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge"],"prefix":"10.1038","volume":"8","author":[{"given":"Yu-Li","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hung","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-260X","authenticated-orcid":false,"given":"Li-Min","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Min","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Yun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Chieh","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bor-Luen","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,16]]},"reference":[{"key":"28281_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1574-6976.2002.tb00601.x","volume":"26","author":"PC McMinn","year":"2002","unstructured":"McMinn, P. C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol. Rev. 26, 91\u2013107 (2002).","journal-title":"FEMS Microbiol. Rev."},{"key":"28281_CR2","doi-asserted-by":"crossref","first-page":"9969","DOI":"10.1128\/JVI.73.12.9969-9975.1999","volume":"73","author":"BA Brown","year":"1999","unstructured":"Brown, B. A., Oberste, M. S., Alexander, J. P. Jr., Kennett, M. L. & Pallansch, M. A. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J. Virol. 73, 9969\u20139975 (1999).","journal-title":"J. Virol."},{"key":"28281_CR3","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0168-1702(95)00087-9","volume":"39","author":"BA Brown","year":"1995","unstructured":"Brown, B. A. & Pallansch, M. A. Complete nucleotide sequence of enterovirus 71 is distinct from poliovirus. Virus Res. 39, 195\u2013205 (1995).","journal-title":"Virus Res."},{"key":"28281_CR4","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1128\/JVI.01019-09","volume":"84","author":"KK Tee","year":"2010","unstructured":"Tee, K. K. et al. Evolutionary genetics of human enterovirus 71: origin, population dynamics, natural selection, and seasonal periodicity of the VP1 gene. J. Virol. 84, 3339\u20133350 (2010).","journal-title":"J. Virol."},{"key":"28281_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3201\/eid0904.020395","volume":"9","author":"MJ Cardosa","year":"2003","unstructured":"Cardosa, M. J. et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg. Infect. Dis. 9, 461\u2013468 (2003).","journal-title":"Emerg. Infect. Dis."},{"key":"28281_CR6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/S1474-4422(08)70207-2","volume":"7","author":"J Qiu","year":"2008","unstructured":"Qiu, J. Enterovirus 71 infection: a new threat to global public health? Lancet Neurol. 7, 868\u2013869 (2008).","journal-title":"Lancet Neurol."},{"key":"28281_CR7","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3345\/kjp.2016.59.10.395","volume":"59","author":"KY Lee","year":"2016","unstructured":"Lee, K. Y. Enterovirus 71 infection and neurological complications. Korean J. Pediatr. 59, 395\u2013401 (2016).","journal-title":"Korean J. Pediatr."},{"key":"28281_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.7774\/cevr.2017.6.1.4","volume":"6","author":"EJ Yi","year":"2017","unstructured":"Yi, E. J., Shin, Y. J., Kim, J. H., Kim, T. G. & Chang, S. Y. Enterovirus 71 infection and vaccines. Clin. Exp. Vaccine Res. 6, 4\u201314 (2017).","journal-title":"Clin. Exp. Vaccine Res."},{"key":"28281_CR9","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S0264-410X(01)00385-1","volume":"20","author":"CN Wu","year":"2001","unstructured":"Wu, C. N. et al. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 20, 895\u2013904 (2001).","journal-title":"Vaccine"},{"key":"28281_CR10","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.vaccine.2008.03.041","volume":"26","author":"HL Chen","year":"2008","unstructured":"Chen, H. L. et al. Expression of VP1 protein in the milk of transgenic mice: a potential oral vaccine protects against enterovirus 71 infection. Vaccine 26, 2882\u20132889 (2008).","journal-title":"Vaccine"},{"key":"28281_CR11","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1016\/j.vaccine.2005.12.047","volume":"24","author":"HF Chen","year":"2006","unstructured":"Chen, H. F., Chang, M. H., Chiang, B. L. & Jeng, S. T. Oral immunization of mice using transgenic tomato fruit expressing VP1 protein from enterovirus 71. Vaccine 24, 2944\u20132951 (2006).","journal-title":"Vaccine"},{"key":"28281_CR12","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/14760584.2016.1191357","volume":"15","author":"Y Zhou","year":"2016","unstructured":"Zhou, Y., Li, J. X., Jin, P. F., Wang, Y. X. & Zhu, F. C. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine. Expert Rev. Vaccines 15, 803\u2013813 (2016).","journal-title":"Expert Rev. Vaccines"},{"key":"28281_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4049\/jimmunol.1601775","volume":"199","author":"PN Boyaka","year":"2017","unstructured":"Boyaka, P. N. Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J. Immunol. 199, 9\u201316 (2017).","journal-title":"J. Immunol."},{"key":"28281_CR14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.imlet.2009.10.005","volume":"128","author":"R Brunner","year":"2010","unstructured":"Brunner, R., Jensen-Jarolim, E. & Pali-Sch\u00f6ll, I. The ABC of clinical and experimental adjuvants\u2014A brief overview. Immunol. Lett. 128, 29\u201335 (2010).","journal-title":"Immunol. Lett."},{"key":"28281_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.4049\/jimmunol.1700348","volume":"199","author":"M Akkaya","year":"2017","unstructured":"Akkaya, M. et al. B cells produce type 1 IFNs in response to the TLR9 agonist CpG-A conjugated to cationic lipids. J. Immunol. 199, 931\u2013940 (2017).","journal-title":"J. Immunol."},{"key":"28281_CR16","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/21645515.2014.1004033","volume":"11","author":"S Iho","year":"2015","unstructured":"Iho, S., Maeyama, J. & Suzuki, F. CpG oligodeoxynucleotides as mucosal adjuvants. Hum. Vaccin. Immunother. 11, 755\u2013760 (2015).","journal-title":"Hum. Vaccin. Immunother."},{"key":"28281_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1385\/IR:24:3:225","volume":"24","author":"BS McKenzie","year":"2001","unstructured":"McKenzie, B. S. et al. Nucleic acid vaccines: tasks and tactics. Immunol. Res. 24, 225\u2013244 (2001).","journal-title":"Immunol. Res."},{"key":"28281_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-11-88","volume":"11","author":"W Meng","year":"2011","unstructured":"Meng, W., Yamazaki, T., Nishida, Y. & Hanagata, N. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists. BMC Biotechnol. 11, 88 (2011).","journal-title":"BMC Biotechnol."},{"key":"28281_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.imbio.2004.02.006","volume":"209","author":"M Jurk","year":"2004","unstructured":"Jurk, M. et al. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology 209, 141\u2013154 (2004).","journal-title":"Immunobiology"},{"key":"28281_CR20","first-page":"606","volume":"12","author":"K Abel","year":"2005","unstructured":"Abel, K. et al. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin. Diagn. Lab. Immunol. 12, 606\u2013621 (2005).","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"28281_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/eji.200324032","volume":"34","author":"J Vollmer","year":"2004","unstructured":"Vollmer, J. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34, 251\u2013262 (2004).","journal-title":"Eur. J. Immunol."},{"key":"28281_CR22","doi-asserted-by":"publisher","first-page":"e57591","DOI":"10.1371\/journal.pone.0057591","volume":"8","author":"YW Lin","year":"2013","unstructured":"Lin, Y. W. et al. Human SCARB2 transgenic mice as an infectious animal model for enterovirus 71. PLoS One 8, e57591 (2013).","journal-title":"PLoS One"},{"key":"28281_CR23","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.4049\/jimmunol.0901466","volume":"183","author":"IM Belyakov","year":"2009","unstructured":"Belyakov, I. M. & Ahlers, J. D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183, 6883\u20136892 (2009).","journal-title":"J. Immunol."},{"key":"28281_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/BF00915547","volume":"7","author":"J Mestecky","year":"1987","unstructured":"Mestecky, J. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7, 265\u2013276 (1987).","journal-title":"J. Clin. Immunol."},{"key":"28281_CR25","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1128\/IAI.72.1.238-246.2004","volume":"72","author":"L Chen","year":"2004","unstructured":"Chen, L., Wang, J., Zganiacz, A. & Xing, Z. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72, 238\u2013246 (2004).","journal-title":"Infect. Immun."},{"key":"28281_CR26","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.4049\/jimmunol.171.3.1602","volume":"171","author":"NP Goonetilleke","year":"2003","unstructured":"Goonetilleke, N. P. et al. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171, 1602\u20131609 (2003).","journal-title":"J. Immunol."},{"key":"28281_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nri1777","volume":"6","author":"MR Neutra","year":"2006","unstructured":"Neutra, M. R. & Kozlowski, P. A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6, 148\u2013158 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"28281_CR28","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.1016\/j.vaccine.2017.07.073","volume":"35","author":"M Ahmed","year":"2017","unstructured":"Ahmed, M. et al. A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice. Vaccine 35, 4983\u20134989 (2017).","journal-title":"Vaccine"},{"key":"28281_CR29","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/S1473-3099(10)70194-8","volume":"10","author":"T Solomon","year":"2010","unstructured":"Solomon, T. et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect. Dis. 10, 778\u2013790 (2010).","journal-title":"Lancet Infect. Dis."},{"key":"28281_CR30","doi-asserted-by":"publisher","first-page":"890","DOI":"10.3390\/ijerph13090890","volume":"13","author":"PC Chang","year":"2016","unstructured":"Chang, P. C., Chen, S. C. & Chen, K. T. The current status of the disease caused by enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int. J. Environ. Res. Public Health 13, 890 (2016).","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"28281_CR31","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.vaccine.2011.12.081","volume":"30","author":"YL Lin","year":"2012","unstructured":"Lin, Y. L. et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30, 1305\u20131312 (2012).","journal-title":"Vaccine"},{"key":"28281_CR32","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.4049\/jimmunol.170.11.5636","volume":"170","author":"PN Boyaka","year":"2003","unstructured":"Boyaka, P. N. et al. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170, 5636\u20135643 (2003).","journal-title":"J. Immunol."},{"key":"28281_CR33","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0264-410X(98)80122-9","volume":"16","author":"Z Moldoveanu","year":"1998","unstructured":"Moldoveanu, Z., Love-Homan, L., Huang, W. Q. & Krieg, A. M. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine 16, 1216\u20131224 (1998).","journal-title":"Vaccine"},{"key":"28281_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nri1329","volume":"4","author":"DM Klinman","year":"2004","unstructured":"Klinman, D. M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4, 249\u2013258 (2004).","journal-title":"Nat. Rev. Immunol."},{"key":"28281_CR35","doi-asserted-by":"publisher","first-page":"e98239","DOI":"10.1371\/journal.pone.0098239","volume":"9","author":"L Tengroth","year":"2014","unstructured":"Tengroth, L. et al. Functional effects of Toll-like receptor (TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells. PLoS One 9, e98239 (2014).","journal-title":"PLoS One"},{"key":"28281_CR36","doi-asserted-by":"publisher","first-page":"5904","DOI":"10.1128\/JVI.00296-15","volume":"89","author":"T Qin","year":"2015","unstructured":"Qin, T. et al. CpG oligodeoxynucleotides facilitate delivery of whole inactivated H9N2 influenza virus via transepithelial dendrites of dendritic cells in nasal mucosa. J. Virol. 89, 5904\u20135918 (2015).","journal-title":"J. Virol."},{"key":"28281_CR37","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.4049\/jimmunol.1402312","volume":"194","author":"H Guo","year":"2015","unstructured":"Guo, H. et al. SCARB2\/LIMP-2 regulates IFN production of plasmacytoid dendritic cells by mediating endosomal translocation of TLR9 and nuclear translocation of IRF7. J. Immunol. 194, 4737\u20134749 (2015).","journal-title":"J. Immunol."},{"key":"28281_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2014.49","volume":"3","author":"S Yamayoshi","year":"2014","unstructured":"Yamayoshi, S., Fujii, K. & Koike, S. Receptors for enterovirus 71. Emerg. Microbes Infect. 3, e53 (2014).","journal-title":"Emerg. Microbes Infect."},{"key":"28281_CR39","doi-asserted-by":"publisher","first-page":"e69858","DOI":"10.1371\/journal.pone.0069858","volume":"8","author":"HW Chang","year":"2013","unstructured":"Chang, H. W. et al. Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice. PLoS One 8, e69858 (2013).","journal-title":"PLoS One"},{"key":"28281_CR40","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.vaccine.2006.06.083","volume":"25","author":"CC Liu","year":"2007","unstructured":"Liu, C. C., Lian, W. C., Butler, M. & Wu, S. C. High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture. Vaccine 25, 19\u201324 (2007).","journal-title":"Vaccine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28281-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28281-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28281-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:37:43Z","timestamp":1671590263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-28281-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,16]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["28281"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-28281-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,16]]},"assertion":[{"value":"20 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"10713"}}